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Guillain-Barre syndrome (GBS) is an eponym for a heterogeneous group of immune-mediated peripheral neuropathies. We
describeacaseofGBSinapatientwhorecievedintravenousstreptokinasetherapyforacuteanteriormyocardialinfarction.Clinical
symptoms are thought to result from streptokinase-antibody complex mediated damage to the local blood-nerve barrier. Patient
was treated with 5-days course of intravenous gammaglobulin and his outcome was good.
1.Introduction
Guillain-Barr´ esyndrome(GBS)isaneponymforaheteroge-
neous group of immune-mediated peripheral neuropathies.
A feature common in all GBS variants is a rapidly evolving
polyradiculoneuropathyprecededbyatriggeringevent,most
often an infection [1]. Some cases of GBS after intravenous
streptokinase administration have been reported previously
[2–5]. We describe a new case of GBS in a patient who
received intravenous streptokinase therapy for acute anterior
myocardial infarction.
2.CaseReport
Aman52-year-oldtaxidriverhasbeenadmittedtoourclinic
with a 1-hour onset chest pain. On electrocardiography,
signs of hyperacute anterior wall myocardial infarction were
evident. Streptokinase 1500000 unit was administrated over
1 hour intravenously. Reperfusion was positive clinically.
Detailed medical history of the patient revealed no exposure
to any drugs or toxins. Additionally, there was no evidence of
any upper respiratory or gastrointestinal infection within the
last 2 months. Medical history was also negative for arterial
orvenousembolism,connectivetissuedisease,andvasculitis.
Hewasdischargedonthe7thdaywithoralaspirin,metopro-
lol, spironolactone, simvastatin, and ramipril. Eleven days
afterdischarge,hecomplainedofprogressiveweaknessonhis
legs and distal parasthesias. He was unable to walk without
aid. On neurological examination, speech was dysarthric,
left peripheral type facial paralysis, glove- and stocking-
type sensorial impairment and absence of deep-tendon
reﬂexes were prominent ﬁndings. Fundoscopic examina-
tion was normal. Cranial MRI revealed nothing. Blood
chemistry was normal except hyperglycemia. Cerebrospinal
ﬂuid (CSF) analysis showed elevation of protein levels
(216mg/dl). CSF cultures were negative. Electromyographic
investigation revealed extensive sensorymotor demyelinized
type peripheral neuropathy, supporting the diagnosis of
GBS. Patient was treated with 5-days course of intravenous
gammaglobulin. Patient’s outcome was good and 1 month
later he was able to walk without aid, and 2 months later he
w a sa b l et ow o r k .
3. Discussion
Streptokinase is a foreign protein derived from group C
streptococci which might induce an immunological reaction
leading to GBS [6]. It is important to remember that
outside of certain institutions with interventional capability,
ﬁbronolytic therapy is still the most common form of
acute-reperfusion therapy that is used for ST-elevation
myocardial infarction. Therefore, streptokinase is still being
used as a ﬁbrinolytic therapy regimen for acute myocardial
infarction worldwide, especially in developing countries and
in some developed countries where facilities of immediate
percutaneous coronary intervention is unavailable. Clinical2 Cardiology Research and Practice
symptoms are thought to result from streptokinase-antibody
complex mediated damage to the local blood-nerve barrier
[7]. GBS after acute myocardial infarction treated with
reteplase also has been reported [8]. It is proposed that high-
creatine kinase from signiﬁcant muscle injury might be a
possible immunological precipitant.
In conclusion, GBS can be seen in the late course of acute
myocardial infarction suggestive of triggered autoimmune
mechanisms. After exclusion of more likely causes, diagnosis
should be considered in patients who develop parasthesia
and muscular weakness after 10–30 days of infarction,
especially if thrombolysed with streptokinase.
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